Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.40 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27769272 | 0.85 | L3MBTL1 (0.44) | ALDH1A1TAAR1CYP1A1CYP1B1NQO2 | |
| SCHEMBL16579705 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TAAR1NQO2CYP3A4CYP1A2 | |
| SCHEMBL17923133 | 0.84 | NOS1 (0.45) | ALDH1A1TAAR1CYP3A4MEN1KMT2A | |
| SCHEMBL13760004 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TAAR1CYP1A1CYP1B1NQO2 | |
| SCHEMBL17878829 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TAAR1CYP1A1CYP1B1NQO2 | |
| SCHEMBL22621679 | 0.73 | PTGS1 (0.38) | ALDH1A1TAAR1CYP1A2MEN1KMT2A | |
| SCHEMBL7936007 | 0.72 | MEN1 (0.41) | ALDH1A1CYP1A2MEN1KMT2AKDM4E | |
| SCHEMBL22491819 | 0.72 | SYK (0.40) | — | |
| SCHEMBL19088240 | 0.72 | SYK (0.36) | ALDH1A1KMT2A | |
| 1,3,5-Trimethoxybenzene SCHEMBL28493 | 0.71 | ALDH1A1 (1.00) | ALDH1A1CYP1A1CYP1B1NQO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319686-B2 | Process for the preparation of tetrahydropyridopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025021193-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-111417635-B | Pyrazolopyrimidines with anti-Respiratory Syncytial Virus (RSV) activity | 爱尔兰詹森科学公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-111315744-B | Heteroaryl tetrahydropyridine compound, preparation method, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| CN-110088104-B | Tetrahydropyridopyrimidine compounds for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098189-A1 | PROCESS FOR THE PREPARATION OF TETRAHYDROPYRIDOPYRIMIDINES | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3717486-B1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-03-23 | — | — | EP | disclosed |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| WO-2017117406-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2016107832-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016107832-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-07 | — | — | WO | disclosed |
| WO-2009103950-A1 | FLUORINATED PYRIDIN-4-0NES | BTG INTERNATIONAL LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| CN-101495461-A | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES INC (US) | 2009-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | TPMT, DPYD, HAVCR2 | ALDH1A1 978/4885TAAR1 1265/4885CYP1A1 92/4885 |
| US-20220098189-A1 | PROCESS FOR THE PREPARATION OF TETRAHYDROPYRIDOPYRIMIDINES | TPMT, DPYD, DHPS | ALDH1A1 457/4885TAAR1 3976/4885CYP1A1 144/4885 |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | RRP15, MAVS, ACE | ALDH1A1 1980/4885TAAR1 4797/4885CYP1A1 922/4885 |
| US-12319686-B2 | Process for the preparation of tetrahydropyridopyrimidines | TPMT, DPYD, DHPS | ALDH1A1 457/4885TAAR1 3976/4885CYP1A1 144/4885 |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPX2, QDPR, TPMT | ALDH1A1 2832/4885TAAR1 2228/4885CYP1A1 712/4885 |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, HAVCR2, QDPR | ALDH1A1 99/4885TAAR1 2677/4885CYP1A1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.